Thus, although toxicity of the original CODE regimen was greater than that of the standard regimen (Murray et al, 1999), the CODE regimen with the G-CSF support is thought to be promising for the treatment of SCLC. The gene discussed is CSF3; the disease is small cell lung carcinoma.